Fuks J Z, Egorin M J, Aisner J, Ostrow S S, Klein M E, Bachur N R, Colvin M, Wiernik P H
Cancer Chemother Pharmacol. 1981;6(2):117-20. doi: 10.1007/BF00262327.
To determine whether dimethylsulfoxide (DMSO) can potentiate antitumor activity of cyclophosphamide (CYC) in patients with squamous cell carcinoma of the lung, 14 patients were treated with 5 l of a 5% or 6% DMSO solution PO over 3 days and 1,500 mg CYC/m2 IV as a 60-min infusion on the third day of treatment. Serial blood, CSF, and urine samples were collected to assess the pharmacokinetics of CYC. Courses were repeated every 3-4 weeks. No antitumor responses were observed. Toxicity was mainly hematologic and similar to that of CYC alone. There was one death from infection during granulocytopenia. Nonhematologic toxicity was moderate to severe and included nausea (14 patients) and vomiting (five patients). The plasma pharmacokinetics of CYC in this study are similar to previously reported results for CYC alone, but the 24-h urinary excretion of CYC in our study is much lower than previously reported. Further studies in tumors more responsive to CYC may be warranted.
为了确定二甲基亚砜（DMSO）能否增强环磷酰胺（CYC）对肺鳞状细胞癌患者的抗肿瘤活性，14例患者接受治疗，连续3天口服5%或6%的DMSO溶液5升，并在治疗的第三天静脉输注1500mg/m²的CYC，输注时间为60分钟。采集系列血液、脑脊液和尿液样本以评估CYC的药代动力学。每3 - 4周重复疗程。未观察到抗肿瘤反应。毒性主要为血液学毒性，与单独使用CYC时相似。在粒细胞减少期间有1例因感染死亡。非血液学毒性为中度至重度，包括恶心（14例患者）和呕吐（5例患者）。本研究中CYC的血浆药代动力学与先前单独报道的CYC结果相似，但本研究中CYC的24小时尿排泄量远低于先前报道。可能有必要对更易对CYC产生反应的肿瘤进行进一步研究。
